You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The closing range uses available history since Aug 31, 2026; less than a full year is stored.
Eocene Ltd.’s Colospan Ltd. entered its first European distribution agreement with Hospital Line SA, granting exclusive rights to market, sell and distribute CG-100 in Greece and Cyprus. A planned launch is expected to run alongside Colospan’s ongoing U.S. pivotal study.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EOCN
this stock
Galmed Pharmaceuticals Ltd.
|
$2.55M | — | +132.3% | — | 0.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$137.57B | +19.7% | +46.2% | 34.9 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.40B | +23.2% | +20.8% | 21.0 | 2.1% |
|
MRNA
Moderna, Inc.
|
$93.61B | +684.5% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.55B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Eocene Ltd.’s Colospan Ltd. entered its first European distribution agreement with Hospital Line SA, granting exclusive rights to market, sell and distribute CG-100 in Greece and Cyprus. A planned launch is expected to run alongside Colospan’s ongoing U.S. pivotal study.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EOCN | -2.5% | -21.6% | — | -22.9% | — |
| SPY | +3.3% | -1.9% | +1.5% | +0.2% | +11.0% |
| vs SPY | -5.7% | -19.7% | — | -23.1% | — |
